Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Vivesto

0,229

 

SEK

 

-2,35 %

Mindre end 1K følgere

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
-2,35%
-1,51%
-0,43%
-21,03%
-14,39%
-23,67%
-78,19%
-96,74%
-98,73%

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Læs mere
Markedsværdi
123,21 mio. SEK
Aktieomsætning
41,66 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
12.8
2025

Delårsrapport Q2'25

11.11
2025

Delårsrapport Q3'25

12.2
2026

Årsrapport '25

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse8.5.2025, 16.53

Carnegie Access: Vivesto: Paccal Vet data expected this summer – Q1(25) review

Vivesto
Selskabsmeddelelse8.5.2025, 08.30

Report from Annual General Meeting in Vivesto AB

Vivesto
Selskabsmeddelelse8.4.2025, 06.00

Notice of Annual General Meeting in Vivesto AB

Vivesto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse1.4.2025, 06.00

Vivesto reports positive Cantrixil results in an animal hematological cancer model

Vivesto
Pressemeddelelse31.3.2025, 15.11

Carnegie Access: Vivesto: Secures the full rights to Cantrixil

Vivesto
Selskabsmeddelelse31.3.2025, 06.00

Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights

Vivesto
Pressemeddelelse18.3.2025, 11.08

Carnegie Access: Vivesto: Licensing deal for Apealea announced with Zhida

Vivesto
Selskabsmeddelelse18.3.2025, 06.15

Vivesto licenses Apealea to China’s Zhida Pharmaceutical

Vivesto
Pressemeddelelse20.2.2025, 16.10

Carnegie Access: Vivesto: Intervju – Statusuppdatering efter Q4 2024-rapporten

Vivesto
Pressemeddelelse16.1.2025, 13.00

Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats

Vivesto
Pressemeddelelse19.12.2024, 10.00

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Vivesto
Pressemeddelelse11.11.2024, 10.33

Vivesto’s Paccal Vet receives Limited Market classification in EU

Vivesto
Selskabsmeddelelse7.11.2024, 09.54

Vivesto signs Apealea option agreement with Zhida Pharmaceutical

Vivesto
Pressemeddelelse1.7.2024, 06.00

Vivesto receives positive Cantrixil preclinical efficacy data

Vivesto
Selskabsmeddelelse23.5.2024, 08.48

Report from Annual General Meeting in Vivesto AB

Vivesto
Selskabsmeddelelse23.4.2024, 06.00

Notice of Annual General Meeting in Vivesto AB

Vivesto
Pressemeddelelse19.3.2024, 12.06

Vivesto to hold live-streamed Paccal Vet R&D Update on March 26

Vivesto
Selskabsmeddelelse7.3.2024, 07.10

Vivesto doses first patient in its clinical Paccal Vet trial

Vivesto
Pressemeddelelse30.1.2024, 07.00

Vivesto's international patent application for XR-18 receives positive decision

Vivesto
Pressemeddelelse28.12.2023, 07.00

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Vivesto
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.